Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX9 for Bowel Delineation in CT Imaging
NCT04789200Phase 2Completed
- Sponsor
- Nextrast Inc
- Start
- Aug 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NX9 Oral Contrast Agent in gastrointestinal carcinoma, gastrointestinal disorders, sponsored by Nextrast Inc. Started Aug 2020; status: completed.
02
Drugs
NX9 Oral Contrast Agent
03
Conditions
gastrointestinal carcinomagastrointestinal disorders
Beyond the preview
Go deeper on NCT04789200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789200.